Oncology Analytics Raises $28 Million Series C Financing Led by Baird Capital

National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund

Learn More

FDA Oncology Drug Approvals

Q2 - 2020

Download the report

Data Driven Utilization Management, Purpose Built for Oncology

Oncology Analytics® provides health plans, providers, and patients with a data-driven, utilization management solution that delivers real-world, evidence-based analytics focused exclusively for oncology

Learn More

A Patient-First Approach to Cancer Care

Learn more about Oncology Analytics’ mission to ensure that all patients receive the best possible evidence-based treatment, tailored to their unique personal needs

Watch the Video

Oncology Analytics named to CB Insights’ Digital Health 150

The most promising 150 private digital health startups working to transform the healthcare industry with new models of primary care to emerging tech solutions for providers

Learn More

Today’s cancer treatments are varied, complicated and costly. Oncology treatment costs are soaring and forecast to hit $105 billion in the US by 2023, driven primarily by availability and favorable reimbursement of new medicines.

Oncology Analytics provides the critical missing link for health plans by helping to manage the total cost of cancer care. By providing access to current, evidence-based, disease-specific analytics on all cancer types and treatment options, backed by board-certified oncology physicians and pharmacists, health plans are able to provide their members with the ability to achieve the best possible outcomes.

Improved outcomes are possible when treatment options are tailored to the unique needs of the patient. Ensuring that patients receive the optimal treatment that balances efficacy, toxicity and affordability lie at the heart of Oncology Analytics’ mission.

Join the conversation

Subscribe to our newsletter

Solutions

e-Prior Authorization

Data-driven through advanced analytics, we help health plans determine the right anti-cancer therapies, then tailor our oncology e-Prior Authorization (ePA) platform to allow treating oncologists to initiate and manage their ePA requests securely through our cloud-based software, which eliminates manual faxing and phone calls, while improving operational efficiency
Read More

Oncology Insights™

Next-generation, real-world data analytic software solution, combined with oncology-focused clinical expertise, equips health plans with superior insight into their provider network, cancer drug trend and spend, cancer treatment decision-making capabilities, and powerful comparative benchmarks
Read More

Pharmacy Consulting

A highly focused group of experienced and board-certified oncology pharmacy professionals, who partner with health plans to keep them up to date on the rapidly changing cancer therapy landscape to improve member care and ensure proper financial impact for the health plan
Read More

News

Oncology Analytics Launches Pharmacy Consulting Services

New Offering Designed to Help Health Plans Navigate the Anti-Cancer Drug Market to Improve Member Treatment Recommendations

Oncology Analytics Raises $28 Million Series C Financing Led by Baird Capital

National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund Atlanta, GA, May 26, 2020 — Oncology Analytics, a leading data analytics and technology-enabled services company dedicated to helping health...

« Older Entries

Articles & Press

#1 Put the Patient First

The following article is the fifth in a five-part series on The Top Five Ways for Health Plans to Manage Oncology Drug Costs While Improving Member Treatment Options.

JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Case vs. BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma

The following article, written by Melissa Pozotrigo, Senior Clinical Oncology Pharmacist at Oncology Analytics, is the final of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held May 29-31, 2020.

« Older Entries